Greater quinidine-induced QTc interval prolongation in women

Robert E. Benton, Mark Sale, David A. Flockhart, Raymond L. Woosley

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Background: Prolongation of the electrocardiographic QT interval by drugs is associated with the occurrence of a potentially lethal form of polymorphic ventricular tachycardia termed torsades de pointes. Women are at greater risk than men for development of this adverse event when taking drugs that prolong the QT interval. To determine whether this may be the result of gender-specific differences in the effect of quinidine on cardiac repolarization, we compared the degree of quinidine-induced QT interval lengthening in healthy young men and women. Methods: Twelve women and 12 men received a single intravenous dose of quinidine (4 mg/kg) or placebo in a single-blind, randomized crossover trial. Total plasma and protein-free concentrations of quinidine and 3-hydroxyquinidine were measured in serum. QT intervals were determined and corrected for differences in heart rate with use of the method of Bazett (QTc = QT/RR1/2). Results: As expected, the mean QTc interval at baseline was longer for women than for men (mean ± SD; 407 ± 7 versus 395 ± 9 ms, P <.05). The slope of the relationship between change in the QTc interval (ΔQTc) from baseline to the serum concentration of quinidine was 44% greater for women than for men (mean ± SE; 42.2 ± 3.4 versus 29.3 ± 2.6 ms/μg per mL, P <.001). These results were not influenced by analysis of 3-hydroxyquinidine, free concentrations of quinidine and 3-hydroxyquinidine, or the JT interval. Conclusions: Quinidine causes greater QT prolongation in women than in men at equivalent serum concentrations. This difference may contribute to the greater incidence of drug-induced torsades de pointes observed in women taking quinidine and has implications for other cardiac and noncardiac drugs that prolong the QTc interval. Adjustment of dosages based on body size alone are unlikely to substantially reduce the increased risk of torsades de pointes in women.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume67
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Quinidine
Torsades de Pointes
Pharmaceutical Preparations
Serum
Body Size
Ventricular Tachycardia
Cross-Over Studies
Blood Proteins
Heart Rate
Placebos
Incidence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Benton, R. E., Sale, M., Flockhart, D. A., & Woosley, R. L. (2000). Greater quinidine-induced QTc interval prolongation in women. Clinical Pharmacology and Therapeutics, 67(4), 413-418.

Greater quinidine-induced QTc interval prolongation in women. / Benton, Robert E.; Sale, Mark; Flockhart, David A.; Woosley, Raymond L.

In: Clinical Pharmacology and Therapeutics, Vol. 67, No. 4, 2000, p. 413-418.

Research output: Contribution to journalArticle

Benton, RE, Sale, M, Flockhart, DA & Woosley, RL 2000, 'Greater quinidine-induced QTc interval prolongation in women', Clinical Pharmacology and Therapeutics, vol. 67, no. 4, pp. 413-418.
Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clinical Pharmacology and Therapeutics. 2000;67(4):413-418.
Benton, Robert E. ; Sale, Mark ; Flockhart, David A. ; Woosley, Raymond L. / Greater quinidine-induced QTc interval prolongation in women. In: Clinical Pharmacology and Therapeutics. 2000 ; Vol. 67, No. 4. pp. 413-418.
@article{90b03328763945a2abf7f8d07b3f483a,
title = "Greater quinidine-induced QTc interval prolongation in women",
abstract = "Background: Prolongation of the electrocardiographic QT interval by drugs is associated with the occurrence of a potentially lethal form of polymorphic ventricular tachycardia termed torsades de pointes. Women are at greater risk than men for development of this adverse event when taking drugs that prolong the QT interval. To determine whether this may be the result of gender-specific differences in the effect of quinidine on cardiac repolarization, we compared the degree of quinidine-induced QT interval lengthening in healthy young men and women. Methods: Twelve women and 12 men received a single intravenous dose of quinidine (4 mg/kg) or placebo in a single-blind, randomized crossover trial. Total plasma and protein-free concentrations of quinidine and 3-hydroxyquinidine were measured in serum. QT intervals were determined and corrected for differences in heart rate with use of the method of Bazett (QTc = QT/RR1/2). Results: As expected, the mean QTc interval at baseline was longer for women than for men (mean ± SD; 407 ± 7 versus 395 ± 9 ms, P <.05). The slope of the relationship between change in the QTc interval (ΔQTc) from baseline to the serum concentration of quinidine was 44{\%} greater for women than for men (mean ± SE; 42.2 ± 3.4 versus 29.3 ± 2.6 ms/μg per mL, P <.001). These results were not influenced by analysis of 3-hydroxyquinidine, free concentrations of quinidine and 3-hydroxyquinidine, or the JT interval. Conclusions: Quinidine causes greater QT prolongation in women than in men at equivalent serum concentrations. This difference may contribute to the greater incidence of drug-induced torsades de pointes observed in women taking quinidine and has implications for other cardiac and noncardiac drugs that prolong the QTc interval. Adjustment of dosages based on body size alone are unlikely to substantially reduce the increased risk of torsades de pointes in women.",
author = "Benton, {Robert E.} and Mark Sale and Flockhart, {David A.} and Woosley, {Raymond L.}",
year = "2000",
language = "English (US)",
volume = "67",
pages = "413--418",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Greater quinidine-induced QTc interval prolongation in women

AU - Benton, Robert E.

AU - Sale, Mark

AU - Flockhart, David A.

AU - Woosley, Raymond L.

PY - 2000

Y1 - 2000

N2 - Background: Prolongation of the electrocardiographic QT interval by drugs is associated with the occurrence of a potentially lethal form of polymorphic ventricular tachycardia termed torsades de pointes. Women are at greater risk than men for development of this adverse event when taking drugs that prolong the QT interval. To determine whether this may be the result of gender-specific differences in the effect of quinidine on cardiac repolarization, we compared the degree of quinidine-induced QT interval lengthening in healthy young men and women. Methods: Twelve women and 12 men received a single intravenous dose of quinidine (4 mg/kg) or placebo in a single-blind, randomized crossover trial. Total plasma and protein-free concentrations of quinidine and 3-hydroxyquinidine were measured in serum. QT intervals were determined and corrected for differences in heart rate with use of the method of Bazett (QTc = QT/RR1/2). Results: As expected, the mean QTc interval at baseline was longer for women than for men (mean ± SD; 407 ± 7 versus 395 ± 9 ms, P <.05). The slope of the relationship between change in the QTc interval (ΔQTc) from baseline to the serum concentration of quinidine was 44% greater for women than for men (mean ± SE; 42.2 ± 3.4 versus 29.3 ± 2.6 ms/μg per mL, P <.001). These results were not influenced by analysis of 3-hydroxyquinidine, free concentrations of quinidine and 3-hydroxyquinidine, or the JT interval. Conclusions: Quinidine causes greater QT prolongation in women than in men at equivalent serum concentrations. This difference may contribute to the greater incidence of drug-induced torsades de pointes observed in women taking quinidine and has implications for other cardiac and noncardiac drugs that prolong the QTc interval. Adjustment of dosages based on body size alone are unlikely to substantially reduce the increased risk of torsades de pointes in women.

AB - Background: Prolongation of the electrocardiographic QT interval by drugs is associated with the occurrence of a potentially lethal form of polymorphic ventricular tachycardia termed torsades de pointes. Women are at greater risk than men for development of this adverse event when taking drugs that prolong the QT interval. To determine whether this may be the result of gender-specific differences in the effect of quinidine on cardiac repolarization, we compared the degree of quinidine-induced QT interval lengthening in healthy young men and women. Methods: Twelve women and 12 men received a single intravenous dose of quinidine (4 mg/kg) or placebo in a single-blind, randomized crossover trial. Total plasma and protein-free concentrations of quinidine and 3-hydroxyquinidine were measured in serum. QT intervals were determined and corrected for differences in heart rate with use of the method of Bazett (QTc = QT/RR1/2). Results: As expected, the mean QTc interval at baseline was longer for women than for men (mean ± SD; 407 ± 7 versus 395 ± 9 ms, P <.05). The slope of the relationship between change in the QTc interval (ΔQTc) from baseline to the serum concentration of quinidine was 44% greater for women than for men (mean ± SE; 42.2 ± 3.4 versus 29.3 ± 2.6 ms/μg per mL, P <.001). These results were not influenced by analysis of 3-hydroxyquinidine, free concentrations of quinidine and 3-hydroxyquinidine, or the JT interval. Conclusions: Quinidine causes greater QT prolongation in women than in men at equivalent serum concentrations. This difference may contribute to the greater incidence of drug-induced torsades de pointes observed in women taking quinidine and has implications for other cardiac and noncardiac drugs that prolong the QTc interval. Adjustment of dosages based on body size alone are unlikely to substantially reduce the increased risk of torsades de pointes in women.

UR - http://www.scopus.com/inward/record.url?scp=0034014806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034014806&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 413

EP - 418

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -